Examiner: NOTTINGHAM, KYLE GREGORY

Tech Center 1700 • Art Units: 1621 1797

This examiner grants 59% of resolved cases

Performance Statistics

59.3%

Allow Rate

-5.7% vs TC avg

149

Total Applications

+34.9%

Interview Lift

1193

Avg Prosecution Days

Based on 108 resolved cases, 2023–2026

2.3%

§101 Eligibility

17.4%

§102 Novelty

34.2%

§103 Obviousness

26.3%

§112 Clarity

App #	Title	Status	Assignee
16276004	Suppression and Inhibition of CDC25B with Safranal-Based Formulations	Final Rejection	United Arab Emirates University
18630030	PRIDOPIDINE AND ANALOGS THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE EYE DISEASE	Non-Final OA	PRILENIA NEUROTHERAPEUTICS LTD.
19045439	COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF OBESITY AND OBESITY-INDUCED DISEASE	Non-Final OA	Apogee Biotechnology Corporation

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.